MedCap (MCAP) Stock Overview
A private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MCAP Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
MedCap AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 483.00 |
| 52 Week High | SEK 677.00 |
| 52 Week Low | SEK 329.00 |
| Beta | 0.52 |
| 1 Month Change | -7.82% |
| 3 Month Change | -10.39% |
| 1 Year Change | 23.21% |
| 3 Year Change | 98.77% |
| 5 Year Change | 144.68% |
| Change since IPO | 4,682.18% |
Recent News & Updates
Recent updates
Estimating The Fair Value Of MedCap AB (publ) (STO:MCAP)
Jan 30
Earnings Troubles May Signal Larger Issues for MedCap (STO:MCAP) Shareholders
Nov 06Is MedCap (STO:MCAP) Using Too Much Debt?
Sep 25A Look At The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)
Aug 28MedCap AB (publ)'s (STO:MCAP) Shares Climb 27% But Its Business Is Yet to Catch Up
Jul 13MedCap (STO:MCAP) Strong Profits May Be Masking Some Underlying Issues
May 07Subdued Growth No Barrier To MedCap AB (publ) (STO:MCAP) With Shares Advancing 28%
May 04Why We Think The CEO Of MedCap AB (publ) (STO:MCAP) May Soon See A Pay Rise
Apr 29Some MedCap AB (publ) (STO:MCAP) Shareholders Look For Exit As Shares Take 34% Pounding
Feb 03We Think MedCap (STO:MCAP) Can Manage Its Debt With Ease
Nov 16MedCap AB (publ)'s (STO:MCAP) Earnings Haven't Escaped The Attention Of Investors
Oct 18Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)
Jun 06MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks Reasonable
May 21Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?
May 04MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price Bounce
Feb 15Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?
Dec 21Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?
May 06These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt Safely
Nov 23We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With Ease
Sep 21Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?
Apr 29MedCap (STO:MCAP) Seems To Use Debt Rather Sparingly
Feb 01Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?
Aug 03Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?
May 27Here's Why I Think MedCap (STO:MCAP) Is An Interesting Stock
Apr 07Imagine Holding MedCap (STO:MCAP) Shares While The Price Zoomed 558% Higher
Mar 15Have Insiders Been Selling MedCap AB (publ) (STO:MCAP) Shares?
Feb 26MedCap (STO:MCAP) Could Easily Take On More Debt
Feb 08Shareholder Returns
| MCAP | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 0.6% | 2.6% | 1.6% |
| 1Y | 23.2% | -13.8% | 5.2% |
Return vs Industry: MCAP exceeded the Swedish Life Sciences industry which returned -16.2% over the past year.
Return vs Market: MCAP exceeded the Swedish Market which returned 4% over the past year.
Price Volatility
| MCAP volatility | |
|---|---|
| MCAP Average Weekly Movement | 5.0% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MCAP has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: MCAP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 592 | Anders Dahlberg | medcap.se/en/ |
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, pharmaceuticals, med tech and assistive tech companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe.
MedCap AB (publ) Fundamentals Summary
| MCAP fundamental statistics | |
|---|---|
| Market cap | SEK 7.25b |
| Earnings (TTM) | SEK 219.80m |
| Revenue (TTM) | SEK 2.11b |
Is MCAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCAP income statement (TTM) | |
|---|---|
| Revenue | SEK 2.11b |
| Cost of Revenue | SEK 871.90m |
| Gross Profit | SEK 1.24b |
| Other Expenses | SEK 1.02b |
| Earnings | SEK 219.80m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 29, 2026
| Earnings per share (EPS) | 14.63 |
| Gross Margin | 58.64% |
| Net Profit Margin | 10.43% |
| Debt/Equity Ratio | 14.8% |
How did MCAP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/20 12:50 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedCap AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Hans Mähler | Nordea Markets |